Results 201 to 210 of about 908,423 (246)

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Unilateral chylothorax in a renal transplant recipient: A case report. [PDF]

Urol Case Rep
Amuda BR, Situmorang GR, Rasyid N.
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

Successful Use of Chimeric Antigen Receptor T-cell (CAR-T) Therapy With Lisocabtagene Maraleucel in a Renal Transplant Recipient With Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL). [PDF]

Cureus
Tai W, Chaudhry F, Shahrour N, Thomas J, Anyadibe A, Oyetoran A, Gopishetty S, Idogun P, Samarapungavan D, Sarmad JH, Jaiyesimi I.   +10 more
europepmc   +1 more source

Metabolomic investigation of cisplatin‐induced acute kidney injury in paediatric cancer patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Cisplatin causes acute kidney injury (AKI) in approximately 46% of paediatric cancer patients who receive it. Serum creatinine (SCr) is a poor biomarker of cisplatin nephrotoxicity, because there is a delay between cisplatin infusion and SCr elevation.
Yong Jin Lim, Amy Thachil, Kelly McMahon, Ross T. Tsuyuki, S. Rod Rassekh, Lesley G. Mitchell, Prasad Devarajan, Cherry Mammen, Bruce C. Carleton, Geoffrey D. E. Cuvelier, Victor A. Lewis, Colin J. D. Ross, Alexandra P. Zorzi, Sylvain Baruchel, Raveena Ramphal, Eric Bouffet, Mathieu Lemaire, Tom D. Blydt‐Hansen, Brad L. Urquhart, The Applying Biomarkers to Minimize Long‐Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group, Tom Blydt‐Hansen, Bruce C. Carleton, Geoff D. E. Cuvelier, Sunil Desai, Prasad Devarajan, Conrad Fernandez, Adam Fleming, Paul Gibson, Caroline Laverdiere, Victor Lewis, Mary L. McBride, Bruno Michon, Shahrad Rod Rassekh, Colin J. D. Ross, Christine Sabapathy, Kirk R. Schultz, Michael Zappitelli, Alexandra Zorzi   +37 more
wiley   +1 more source

Conservative Management of Thrombotic Microangiopathy in a Renal Transplant Recipient: The Importance of Early Recognition. [PDF]

Clin Case Rep
Matarneh AS, Sardar S, Akkari AR, Mohan P, Trivedi N, Kaur G, Ghahramani N.   +6 more
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Fever of Unknown Origin in a Renal Transplant Recipient. [PDF]

Indian J Nephrol
Mohanasundaram S, Srinivasaprasad ND, Fernando E, Thirumalvalavan K, Surendran S, Annadurai P.   +5 more
europepmc   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

First full intracorporeal robotic cystectomy and neobladder in a renal transplant recipient. [PDF]

J Surg Case Rep
Tillou X, Le Bloa L, Courteille V, Bechade C, Waeckel T.   +4 more
europepmc   +1 more source